14:00 - 14:15 Opening & welcome

• MC Béné (chair of the Scientific Working Group on Diagnosis in hematological diseases)

14:15 - 15:45 Session 1: Tools of the trade (1)

Chair: TBC

• Useful secrets of automated cell counters
  M Eveillard (France)
• Update on digital morphology
  J Burthem (United Kingdom)
• Elusive cells "for the morphologist eye only''
  T Haferlach (Germany)

15:45 - 16:15 Coffee break

16:15 - 18:15 Session 2: Tools of the trade (2)

Chair: TBC

• Unsupervised machine learning in flow cytometry
  F Lacombe (France)
• Improvements in cytogenetics from karyotype to optical genome
  C Mecucci (Italy)
• NGS and beyond, including liquid biopsy and digital PCR
  T Haferlach (Germany)
• Artificial intelligence in pathology: support or menace?
  G Zini (Italy)

18:15 - 19:15 Satellite symposium

19:15 - 20:15 Welcome Reception

09:00 - 10:30 Session 3: The blast cell

• Integrated diagnosis and follow-up of acute lymphoblastic leukemia
  A Porwit (Sweden)
• Integrated diagnosis and follow-up of acute myeloblastic leukemia
  W Kern (Germany)
• Targeting leukemic cells: bi(multi)specifics and CAR-T cells
  C Müller Tidow (Germany)

10:30 - 11:00 Coffee break

11:00 - 12:30 Session 4: CD5+ B-lymphocyte

Chair: TBC

• Integrated differential diagnosis and follow-up of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)
  A Rawstron (United Kingdom)
• Altered pathways in the pathophysiology of CLL and MCL: towards guided therapy?
  LM Fornecker (France)
• Selected oral communications on CLL and MCL from abstracts
  Speaker TBC

12:30 - 14:00 Lunch break

13:00 - 14:00 Satellite symposium

14:00 - 15:30 Session 5: Lymphoma cells

Chair: TBC

• Integrated diagnosis of aggressive Non Hodgkin lymphoma (including pathology, FISH and molecular hematology)
  A Porwit (Sweden)
• The Sternberg cell: a model of lymphocyte exhaustion
  Speaker TBC
• The conundrum of T-cell lymphomas
  O Tournilhac (France)

15:30 - 16:00 Coffee break

16:00 - 17:30 Session 6: The CML cell

Chair: TBC

• Pathophysiology of BCR-ABL applied to diagnosis
  FX Mahon (France)
• When MRD monitoring leads to stop therapy
  S Saussele (Germany)
• Patient testimonial
  Speaker TBC

17:30 - 18:30 Session 7: Oral abstracts

09:00 - 10:30 Session 8: Myelodysplastic cells (MDS) and myeloproliferative neoplasms (MPN)

• MDS integrated diagnosis: the (still) neglected place of flow cytometry
  A Van Loosdrecht (the Netherlands)
• Integrated diagnosis and targeted therapies in MDS and MPN
  Speaker TBC

10:30 - 11:00 Coffee break

11:00 - 12:30 Session 9: Other cells

Chair: TBC

• Paroxysmal nocturnal hemoglobinuria clones: pathophysiology, diagnosis and complement blockade
  A Risitano (Italy)
• Mastocytosis: from morphology to targeted therapy
  P Valent (Austria)
• Myeloma: targeted therapies and follow up
  M Eveillard (France)

12:30 - 14:00 Lunch break and farewell